Category: Prescription Drugs
Most Popular Types: Ampyra
See also: Fampridine (4-AP immediate release)
Sort by: Helpfulness | Most Recent
4 patient evaluations for Dalfampridine (4-AP extended release) taken for the purpose of 'MS (Multiple Sclerosis)' with a perceived effectiveness rating of
| Date | Dosage | Perceived effectiveness | Side Effects | Adherence | Burden |
|---|---|---|---|---|---|
| May 15, 2013 | 10 mg Daily |
| Date | Dosage | Perceived effectiveness | Side Effects | Adherence | Burden |
|---|---|---|---|---|---|
| Jan 04, 2011 | 10 mg Daily |
| Date | Dosage | MS (Multiple Sclerosis) Perceived effectiveness | Walking problems Perceived effectiveness | Imbalance when walking Perceived effectiveness | Unsteady gait Perceived effectiveness | Side Effects | Adherence | Burden |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2010 | 20 mg Daily |
| Date | Dosage | MS (Multiple Sclerosis) Perceived effectiveness | Improve mobility Perceived effectiveness | Side Effects | Adherence | Burden |
|---|---|---|---|---|---|---|
| Jun 24, 2010 | 20 mg Daily |
33 additional evaluations for Dalfampridine (4-AP extended release) are not currently shared publicly.